Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) Director Carl L. Gordon sold 50,976 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $10.00, for a total transaction of $509,760.00. Following the sale, the director now owns 756,258 shares in the company, valued at $7,562,580. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Terns Pharmaceuticals Trading Down 0.6 %
Shares of NASDAQ:TERN traded down $0.06 on Wednesday, hitting $9.64. The company had a trading volume of 2,347,435 shares, compared to its average volume of 999,479. The business has a 50 day moving average of $7.01 and a 200 day moving average of $6.46. Terns Pharmaceuticals, Inc. has a 52-week low of $3.26 and a 52-week high of $10.03. The company has a market cap of $623.52 million, a PE ratio of -7.65 and a beta of -0.37.
Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. As a group, equities analysts predict that Terns Pharmaceuticals, Inc. will post -1.41 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $15.00 target price on shares of Terns Pharmaceuticals in a report on Tuesday, April 30th. UBS Group reduced their price objective on Terns Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 27th. Finally, HC Wainwright restated a “neutral” rating and issued a $5.50 price target on shares of Terns Pharmaceuticals in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.50.
Read Our Latest Report on TERN
Terns Pharmaceuticals Company Profile
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Featured Articles
- Five stocks we like better than Terns Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- Real Estate Stock Signals a Boom in Manufacturing Activity
- What is a Dividend King?
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- Technology Stocks Explained: Here’s What to Know About Tech
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.